Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar

August 8, 2024

Read Time:6 Second

The success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

Michael Jordan’s 23XI Racing team sues NASCAR and CEO Jim France

Michael Jordan's racing team and fellow team Front Row Motorsports said NASCAR has used anticompetitive practices to prevent fair compensation...

October 2, 2024

Stellantis U.S. auto sales extend freefall in third quarter

Stellantis reported U.S. sales Tuesday of 305,294 from July through September, a 19.8% decline from the third quarter of 2023.

October 2, 2024

Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other...

October 2, 2024

500 Starbucks locations have voted to unionize as labor talks continue

Baristas at a Starbucks in Bellingham, Washington, voted to unionize on Monday, becoming the 500th location to join Starbucks Workers...

October 1, 2024

Harris wants to stand out as the pro-cannabis candidate. The industry isn’t convinced yet

Vice President Harris said she supports legalizing cannabis. This follows Trump's comments last month signaling his support. Industry leaders aren't...

October 1, 2024

Nike reports earnings after the bell. Here’s what Wall Street expects

Nike is in a reset after critics say it lost sight of innovation and ceded share to competitors. Its CEO...

October 1, 2024

Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar

About Post Author

Wall Street Today

Other

Business